Jasmin Elurbide

This study identifies altered epigenetic regulators and metabolic genes in cholangiocarcinoma, linking them to poor prognosis and metabolic-epigenetic crosstalk.

This study identifies PRMT1 as a critical driver of cholangiocarcinoma growth and immune evasion, showing its inhibition enhances antitumor immunity and synergizes with immunotherapy.

This study shows that inhibiting G9a enhances the effectiveness of immune checkpoint inhibitors in hepatocellular carcinoma by improving tumor immunogenicity and T cell infiltration.